Abstract Introduction: Chronic pain (CP) affects 35.0%–51.3% of the UK population, with 67%–88% reporting sleep disturbances. Cannabis‐based medicinal products (CBMPs)…
Abstract The aim of this study was to assess changes in validated patient-reported outcome measures after initiation of cannabis-based medicinal…
Abstract Introduction: : There are limited therapeutic options for individuals with fibromyalgia. The aim of this study is to analyze…
Abstract Cannabis‐based medicinal products (CBMPs) are an emerging therapeutic option in the management of primary chronic pain, using the role…
Abstract Aim: Cannabis‐based medicinal products (CBMPs) are prescribed with increased frequency, despite a paucity of high‐quality randomized controlled trials. The…